-
1.发明公开IMMUNO IMAGING AGENT FOR USE WITH ANTIBODY-DRUG CONJUGATE THERAPY 有权IMMUNKONTRASTMITTELFÜRANTIKÖRPER-WIRKSTOFF-KONJUGAT-THERAPIE
公开(公告)号：EP2953977A1
公开(公告)日：2015-12-16
申请号：EP14717073.2
申请日：2014-02-05
申请人： SANOFI
CPC分类号： C07K16/3092 , C07K2317/24 , C07K2317/35 , C07K2317/56 , C07K2317/626 , C07K2317/64 , C07K2317/92 , C07K2317/94 , C07K2319/21 , G01N2800/52
摘要： The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for
in vivo detection and quantification of the tumor-associated MUCl-sialoglycotope, CA6.摘要翻译： 本发明涉及一种基于人源化单克隆抗体DS6的伴随诊断抗体样结合蛋白，用作用于体内检测和定量肿瘤相关MUCI-唾液酸多糖CA6的诊断工具。
-
">2.发明公开
公开(公告)号：EP2486058A1
公开(公告)日：2012-08-15
申请号：EP10771381.0
申请日：2010-10-08
申请人： SANOFI
发明人： HUBER, Jochen , BLANCHE, Francis , DABDOUBI, Tarik , SOUBRIER, Fabienne , FOCKEN, Ingo , KRUIP, Jochen , HEERMEIER, Katherin , LANGE, Christian
CPC分类号： C07K16/28 , A61K38/00 , C07K2317/92
摘要： The present invention relates to a polypeptide or polypeptide complex comprising at least the two amino acid sequences arranged to allow for specific binding to the "receptor for advanced glycation endproducts" (RAGE), one or more nucleic acid(s) coding for the polypeptide or polypeptide complex, a cell producing an antibody against RAGE, a pharmaceutical composition comprising at least one polypeptide or nucleic as defined above, optionally for treating a RAGE-related disease or disorder and a method of diagnosing a RAGE-related disease or disorder.
-
3.发明公开HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF 有权杂环化合物，它们的制备方法，含有这些化合物和它们的药物使用
公开(公告)号：EP2310372A2
公开(公告)日：2011-04-20
申请号：EP09776990.5
申请日：2009-07-07
申请人： Sanofi-Aventis
IPC分类号： C07D213/69 , C07D319/06 , C07D237/16 , C07D405/12 , A61K31/44 , A61K31/50 , A61K31/357 , A61P3/00 , A61K31/4433
CPC分类号： C07D213/69 , C07D237/16 , C07D319/06 , C07D405/12
摘要： Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, T and Y have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example for the treatment of the metabolic syndrome, insulin resistance, obesity and diabetes.
-
公开(公告)号：EP3902823A1
公开(公告)日：2021-11-03
申请号：EP19836843.3
申请日：2019-12-23
申请人： SANOFI
-
5.发明公开NOVEL ANTAGONIST ANTIBODIES AND THEIR FAB FRAGMENTS AGAINST GPVI AND USES THEREOF 有权新型拮抗剂抗体及其Fab片段AGAINST GPVI及其用途
公开(公告)号：EP2513147A2
公开(公告)日：2012-10-24
申请号：EP10813028.7
申请日：2010-12-17
申请人： SANOFI
发明人： BAURIN, Nicolas , BLANCHE, Francis , CAMERON, Béatrice , CORVEY, Carsten , DABDOUBI, Tarik , ENGEL, Christian , FLORIAN, Peter , FOCKEN, Ingo , KROLL, Katja , KRUIP, Jochen , LANGE, Christian , LANGER, Thomas , LORENZ, Martin , MIKOL, Vincent , RAO, Ercole , WONEROW, Peter
IPC分类号： C07K16/28
CPC分类号： C07K16/28 , A61K2039/505 , C07K1/1075 , C07K16/2803 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： FR2009/113 PCT PATENT APPLICATION TITLE Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof SANOFI-AVENTIS ABSTRACT The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab. The invention concerns a method for prevention of platelet activation when an anti-GP VI Fab is used.
-
6.发明授权Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof 有权杂环化合物，它们的制备方法，含有这些化合物和它们的药物使用
公开(公告)号：EP2310372B1
公开(公告)日：2012-05-23
申请号：EP09776990.5
申请日：2009-07-07
申请人： SANOFI
IPC分类号： C07D213/69 , C07D319/06 , C07D237/16 , C07D405/12 , A61K31/44 , A61K31/50 , A61K31/357 , A61P3/00 , A61K31/4433
CPC分类号： C07D213/69 , C07D237/16 , C07D319/06 , C07D405/12
摘要： Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, T and Y have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example for the treatment of the metabolic syndrome, insulin resistance, obesity and diabetes.
-
公开(公告)号：EP4347640A1
公开(公告)日：2024-04-10
申请号：EP22726534.5
申请日：2022-05-27
申请人： Sanofi
-
-
公开(公告)号：EP3504233A1
公开(公告)日：2019-07-03
申请号：EP17758138.6
申请日：2017-08-24
申请人： Sanofi
-
公开(公告)号：EP3319986A1
公开(公告)日：2018-05-16
申请号：EP16736427.2
申请日：2016-07-06
申请人： SANOFI
发明人： CORVEY, Carsten , STUMP, Heike , KRUIP, Jochen , LANGE, Christian , FOCKEN, Ingo , RAT, Dorothea , STUEDEMANN, Thomas , RASSER, Hans-Falk , SCHAEFER, Juergen , CALANDRA, Bernhard , REY, Astrid , MOUREZ, Michael , FRAISSE, Laurent , ROTHE, Christine , ALLERSDORFER, Andrea , WIEDENMANN, Alexander , HINNER, Marlon , LUNDE, Bradley , JENSEN, Kristian , HÜLSMEYER, Martin
IPC分类号： C07K14/47
CPC分类号： C07K14/47 , A61K38/00 , C07K2319/00 , C07K2319/21 , C07K2319/22 , C07K2319/30 , C07K2319/50 , C07K2319/70
摘要： The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.011 秒)
